BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Toll-like receptor 3 (TLR3)

April 2, 2015 7:00 AM UTC

In vitro and mouse studies suggest a selective TLR3 agonist could boost the effectiveness of cancer immunotherapy. The TLR3 agonist consisted of a region of the dsRNA measles virus linked to a phospho...